Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomised, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST Fibrin Pad in Controlling Mild or Moderate Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic and (non-cardiac) Thoracic Surgery in Paediatric Patients

Trial Profile

A Prospective, Randomised, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST Fibrin Pad in Controlling Mild or Moderate Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic and (non-cardiac) Thoracic Surgery in Paediatric Patients

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fibrin (Primary)
  • Indications Surgical blood loss
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ethicon

Most Recent Events

  • 14 Jul 2016 Planned End Date changed from 1 Nov 2017 to 31 Dec 2018.
  • 16 Jun 2016 Planned End Date changed from 1 Nov 2018 to 1 Nov 2017.
  • 05 Mar 2016 According to Ethicon media release, data from this trial is part of a pending regulatory submission to the U.S. Food and Drug Administration ("FDA") to expand the indication for EVARREST in the United States.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top